Almac Teams up with the Leukemia and Lymphoma Society

Almac Clinical Technologies announced today their partnership with The Leukemia and Lymphoma Society. Almac and the Leukemia & Lymphoma Society (LLS) share a common commitment to the advancement of human health and hope to aid in finding a cure to leukemia, lymphoma, Hodgkin’s disease and myeloma.

Almac will be heavily involved in several major events organized by LLS. ‘Light the Night’ is one of many walks that attracts patients, survivors, families, friends, and those who want to be a part of finding a cure. Participants work to raise money in the months previous to this walk, and celebrate their efforts with a red and white lit balloon parade. In addition to Almac being a major sponsor of the event, Almac employees will be involved as volunteers and participants in the walk.

‘Team in Training’ is the world’s largest endurance training program and the Society’s signature fundraising campaign. Almac will be participating as a Gold Partner in the event and will also be sponsoring employees as they participate with the program to prepare for and ultimately complete a marathon, half marathon or triathlon.

As a leader in the clinical trial industry, Almac is committed to personal and financial involvement in efforts to advance the research and development that takes place withing the Society. Jim Murphy, President and Managing Director of Almac Clinical technologies commented on the partnership, “Almac is proud of it’s affiliation with the Leukemia and Lymphoma Society and is very hopeful that we can help them in their efforts to find a cure.”

About LLS

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society®, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world’s largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society’s mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit www.LLS.org or call the Society’s Information Resource Center (IRC), a call center staffed by master’s level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

About Almac

Almac Clinical Technologies is a division of Almac that specializes in interactive technology and service solutions to increase the quality and efficiency of the clinical trial process. Our solutions include Interactive Voice and Web Response Systems (IXRS™) for patient randomization, tracking and clinical supply management, iTrial EDC for electronic case report form data collection, electronic patient reported outcome data collection, and web drug reconciliation.

The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, diagnostic/genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors. The company is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.

Contact: Meghan Adams US: 267-685-4284 / [email protected]

Website: almacgroup.com